

1 1. Title Page

2 **Title:**

3 CD4⁺ T cell mitochondrial genotype in Multiple Sclerosis: a cross-sectional and longitudinal analysis

4

5 **Authors:**

6 Filipe Cortes-Figueiredo ^{1,2,3}, Susanna Asseyer ^{2,3}, Claudia Chien ^{2,3}, Hanna G. Zimmermann ^{2,4},

7 Klemens Ruprecht ⁵, Tanja Schmitz-Hübsch ^{2,3}, Judith Bellmann-Strobl ^{2,3}, Friedemann Paul ^{2,3,*},

8 Vanessa A. Morais ^{1*}

9

10 **Affiliations:**

11 ¹ VMorais Lab – Mitochondria Biology & Neurodegeneration, Instituto de Medicina Molecular João

12 Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

13 ² Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for

14 Molecular Medicine in the Helmholtz Association & Charité – Universitätsmedizin Berlin, Berlin,

15 Germany.

16 ³ NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of

17 Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,

18 Germany

19 ⁴ Einstein Center Digital Future, Berlin, Germany

20 ⁵ Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie

21 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

22

23 **Co-corresponding authors (*):**

24 Vanessa A. Morais; vmorais@medicina.ulisboa.pt

25 Friedemann Paul; friedemann.paul@charite.de

26

27 2. Abstract

28 Multiple Sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous
29 system (CNS), with a largely unknown etiology, where mitochondrial dysfunction significantly
30 contributes to neuroaxonal loss and brain atrophy. Mirroring the CNS, peripheral immune cells from
31 patients with MS, particularly CD4⁺ T cells, show inappropriate mitochondrial phenotypes and/or
32 oxidative phosphorylation (OxPhos) insufficiency, with a still unknown contribution of mitochondrial
33 DNA (mtDNA). We hypothesized that mitochondrial genotype in CD4⁺ T cells might influence MS
34 disease activity and progression.

35 Thus, we performed a retrospective cross-sectional and longitudinal study on patients with a recent
36 diagnosis of either Clinically Isolated Syndrome (CIS) or Relapsing-Remitting MS (RRMS) at two
37 timepoints: six months (VIS1) and 36 months (VIS2) after disease onset. Our primary outcomes were
38 the differences in mtDNA extracted from CD4⁺ T cells between: (I) patients with CIS/RRMS (PwMS)
39 at VIS1 and age- and sex-matched healthy controls (HC), in the cross-sectional analysis, and (II)
40 different diagnostic evolutions in PwMS from VIS1 to VIS2, in the longitudinal analysis.

41 We successfully performed mtDNA whole genome sequencing (WGS) (mean coverage: 2055.77
42 reads/base pair) in 183 samples (61 triplets). Nonetheless, mitochondrial genotype was not
43 associated with a diagnostic of CIS/RRMS, nor with longitudinal diagnostic evolution.

44

45 3. Keywords

46 multiple sclerosis; case-control study; cohort study; mitochondrial DNA; CD4⁺ T cell

47

48 4. Introduction

49 Multiple Sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disease with a
50 largely unknown etiology, secondary to an autoimmune demyelination in the central nervous
51 system (CNS). Histopathologically, it is characterized by gliosis, oligodendrocyte death, and
52 neuroaxonal loss [1]. Worldwide, approximately 2.8 million patients with MS deal with significant
53 levels of disability [2].

54 Several studies have shown that the autoimmune response seen in MS mostly derives from a
55 dysfunctional autoreactive CD4⁺ T cell compartment [3–5], although other pro-inflammatory cells,
56 such as B cells and myeloid cells, seem to be implicated as well [6]. Recently, mitochondria have also
57 been shown to play a role in driving MS disease activity and progression. In the CNS, mitochondrial
58 dysfunction has been found to be a critical trigger for neuroaxonal loss and brain atrophy [7,8]. In
59 the peripheral immune compartment, CD4⁺ T cells from patients with MS show oxidative
60 phosphorylation (OxPhos) insufficiency [9–11], which, in animal models, has been linked to an
61 exacerbation of CNS autoimmune-mediated inflammation [12,13].

62 In parallel, mutations in mitochondrial DNA (mtDNA), which is responsible for encoding 22 transfer
63 RNAs (tRNAs), two ribosomal RNAs (rRNAs), and 13 proteins of the OxPhos chain, as well as
64 particular haplogroups, which are inherited mutational patterns that may be classified into
65 phylogenetic clusters [14,15], have also been associated with an increased risk of MS, albeit not
66 consistently [16–20].

67 Interestingly, mtDNA polymorphisms have been shown to modulate both metabolism and immunity
68 [21,22], and mtDNA variants have significant tissue-specificity, including in T cells [23]. Nonetheless,
69 whether the aforementioned CD4⁺ T cell OxPhos dysfunction in patients with MS is an inherent
70 consequence of the particular mitochondrial genotype of this immune subset remains unknown.

71 We hypothesized that mitochondrial genotype in CD4⁺ T cells might influence MS disease activity
72 and progression. Thus, we aimed to explore the differences in mtDNA extracted from CD4⁺ T cells
73 between patients with a recent diagnosis of either Clinically Isolated Syndrome (CIS) or Relapsing-
74 Remitting MS (RRMS) and healthy controls (HC). We also analyzed longitudinal mtDNA changes in
75 patients with CIS/RRMS (PwMS).

76

77 5. Materials and Methods

78 5.1. Cohort description

79 We performed an observational retrospective evaluation of prospectively collected data within the
80 Berlin CIS-Cohort (reference: NCT01371071) [24] at the Charité — Universitätsmedizin Berlin, Berlin,
81 Germany. Berlin CIS-Cohort's inclusion criteria are: (I) age ≥ 18 years and (II) diagnosis of either
82 Clinically Isolated Syndrome (CIS) within six months from symptom onset or of Relapsing-Remitting

83 Multiple Sclerosis (RRMS) within two years from symptom onset, according to the 2017 revisions of
84 the McDonald criteria [25].

85 To address the disease activity and progression of patients with CIS/RRMS (PwMS), the following
86 variables were assessed on each clinical visit: number of relapses and time to last relapse; expanded
87 disability status scale (EDSS) and Multiple Sclerosis functional composite (MSFC) scores; brain MRI:
88 T2 hyperintense lesions and T1 gadolinium-enhancing lesions; and optical coherence tomography
89 (OCT): peripapillary retinal nerve fiber layer (RNFL) thickness and ganglion cell-inner plexiform layer
90 (GCIPL) volume. Additionally, we assessed if patients fulfilled the criteria for no evidence of disease
91 activity (NEDA)-3, namely, absence of new relapses, on MRI: no T1 gadolinium-enhancing lesions
92 and no new or enlarging T2 hyperintense lesions and the absence of EDSS worsening. Details of MRI,
93 OCT, and NEDA-3 were described earlier [26]. Finally, blood samples were collected and,
94 subsequently, peripheral blood mononuclear cells (PBMCs) were isolated. Further details on the
95 methodology used for collection and analysis of clinical data may be found in Section 1 of the
96 Supplementary Information.

97 PwMS were included in this study if biological samples and a clinical assessment were available for
98 two clinical visits: six months (VIS1) and 36 months (VIS2) after disease onset. Recruitment of HC
99 without a family history of MS was finalized in May 2019; HC were matched to PwMS in a 1:1 ratio
100 according to sex and a maximum age difference of five years.

101 Our primary outcomes were a mitochondrial genotype comparison between: (I) PwMS and HC in
102 the cross-sectional analysis and (II) different diagnostic evolutions from VIS1 to VIS2 in the
103 longitudinal analysis, namely, CIS in both clinical visits, a conversion from CIS to RRMS, and RRMS in
104 both clinical visits.

105 Since mtDNA whole genome sequencing (WGS) in CD4⁺ T cells from PwMS was unreported in the
106 literature, a pilot study with 20 triplets (20 PwMS at VIS1&VIS2 and 20 age- and sex-matched HC)
107 was performed to determine the appropriateness of the sample size through the Dupont method
108 [27].

109

110 5.1.1. Ethical approval

111 The institutional review board (IRB)'s approval was obtained by the Ethics Committee of the Charité
112 — Universitätsmedizin Berlin (application number: EA1/182/10), informed consents were given by
113 every subject, and the study followed the standards of the Declaration of Helsinki [28].

114

115 5.2. Sample processing

116 5.2.1. CD4⁺ T cell enrichment and flow cytometry analysis

117 PBMC sample processing was performed at the same time for each triplet (PwMS at VIS1&VIS2 and
118 HC), to minimize differences within processing. The MojoSort™ Human CD4 T Cell Isolation Kit
119 (#480010, BioLegend, San Diego, CA, USA) was used for CD4⁺ T cell enrichment, in accordance with
120 the manufacturer's instructions.

121 To assess whether CD4⁺ T cell enrichment was achieved, flow cytometry was performed in a BD
122 LSRFortessa™ X-20 Cell Analyzer (BD Biosciences, Franklin Lakes, NJ, USA) on a subset of samples
123 (before and after magnetic enrichment). The following antibodies were used: CD14-eFluor450
124 (#48014941, clone 61D3, eBioscience™, Thermo Fisher Scientific, Waltham, MA, USA); CD19-Alexa
125 Fluor 647 (#302222, clone H1B19, BioLegend, San Diego, CA, USA); CD3-PerCP-Cy5.5 (#45003741,
126 clone OKT3, eBioscience™, Thermo Fisher Scientific, Waltham, MA, USA); CD4-BV711 (#317439,
127 clone OKT4, BioLegend, San Diego, CA, USA); and CD56-PE-Cy7 (#25056741, clone CMSSB/NCAM,
128 eBioscience™, Thermo Fisher Scientific, Waltham, MA, USA).

129 Regarding the gating strategy, CD4⁺ T cells were defined as CD3⁺CD4⁺CD19⁻CD56⁻ single cells (Figure
130 S5 and Figure S6). A detailed protocol and additional details regarding the methodology used for
131 CD4⁺ T cell enrichment and flow cytometry may be found in Section 2 of the Supplementary
132 Information.

133

134 5.2.2. DNA extraction and mtDNA sequencing, including bioinformatic processing and data analysis

135 Similarly, DNA extraction was performed at the same time for each triplet with the QIAamp® DNA
136 Blood Midi Kit (QIAGEN GmbH, Hilden, Germany), according to the manufacturer's instructions.

137 Samples were sequenced with the Applied Biosystems™ Precision ID mtDNA Whole Genome Panel
138 (Thermo Fisher Scientific, Waltham, MA, USA) at IPATIMUP — Instituto de Patologia e Imunologia
139 Molecular da Universidade do Porto (Porto, Portugal). Libraries were prepared using the Ion Chef™

140 automated protocol and samples were run on 530™ chips with the Ion Torrent™ Ion S5™ (Thermo
141 Fisher Scientific, Waltham, MA, USA). Samples with a coverage uniformity < 85% and/or a mean
142 coverage < 1500 reads were resequenced.

143 Regarding bioinformatic processing, the PrecisionCallerPipeline (PCP) pipeline [29] was used, with
144 mutserve v2 [30,31] for variant calling, HaploGrep v2.4.0 [15] for haplogroup calling, and
145 Haplocheck v1.3.3 [31] for a contamination check. To account for possible false positives, variants
146 with a variant level (VL) ≥ 10% were only accepted if they were found with both the PCP pipeline
147 and the Ion Torrent Suite™ Software (TSS), while variants below TSS's limit of detection (10%) and
148 solely present with PCP were filtered in accordance with: (I) sequencing indicators for variant
149 reliability (normalized coverage, coverage ratio, mean value of reported nuclear insertions of
150 mitochondrial DNA [NUMTs], and the distance to the amplicon's edge); and (II) previous reports of
151 the same variants in curated mtDNA databases. Variants only present in TSS were excluded [29].

152 Data analysis was performed with R version 4.1.1 [32] and Excel 2016 (Microsoft Corporation,
153 Redmond, WA, USA).

154 The level of statistical significance was set at a two-sided *p*-value < 0.05 for all tests and multiple
155 comparison testing was adjusted with false discovery rate (FDR). Whenever data was missing, it was
156 censored from the analysis. Reporting followed the standards from STROBE [33] and its extension
157 STREGA [34].

158 A detailed description of the methodology regarding DNA extraction, bioinformatic processing, and
159 data analysis may be found in Section 3 of the Supplementary Information.

160

161 6. Results

162 6.1. Cohort description

163 Overall, 61 PwMS were included in this study cohort (Table 1). Most patients presented with RRMS
164 at both clinical visits, mean follow-up time between VIS1 and VIS2 was 30.50 ± 1.27 (mean ± SD)
165 months. Approximately one third of the PwMS (N=20) suffered a relapse between VIS1 and VIS2,
166 while PwMS under MS immunomodulatory treatment increased from 26.23% to 47.54%. The
167 average age difference between PwMS at VIS1 and HC was 2.06 ± 1.31 (mean ± SD) years.

168 As mentioned previously, a pilot study with 20 triplets (20 PwMS at VIS1&VIS2 and 20 age- and sex-
169 matched HC) was performed to determine the appropriateness of the sample size through the
170 Dupont method [27]. Following WGS data analysis of this subset, a 35% discordance in prevalence
171 was detected for deleterious variants in Complex I — 55% for PwMS at VIS1 (discordant prevalence:
172 45%) vs. 20% for HC (discordant prevalence: 10%). Hence, the sample size was adequate according
173 to this endpoint.

174

175 6.2. CD4⁺ T cell enrichment, DNA extraction, and WGS quality

176 Following the magnetic enrichment in CD4⁺ T cells, we obtained a wide range in the number of cells
177 and cell mortality, for all subject types (Table 2 and Table S5). In comparison with HC, PwMS at VIS1
178 showed a lower number of cells (mean difference of 0.65 million, 95% confidence interval [CI] 0.16–
179 1.14; paired t-test adjusted with FDR). In comparison with VIS2, cells from PwMS at VIS1 had lower
180 mortality (mean difference of 2.77%, 95% CI 0.56–4.97%; paired t-test adjusted with FDR).

181 Nonetheless, a significant increase in CD4⁺ T cells (CD3⁺ CD4⁺ CD56⁻ CD19⁻) was achieved (Figure 1A,
182 and Table S3: mean fold change in paired samples of 2.59, 95% CI 2.31–2.87; paired t-test, $N=49$),
183 regardless of subject type (Table S4).

184 Subsequently, after the extraction of DNA, variable amounts of DNA were achieved (Table 2 and
185 Table S5). In comparison with PwMS at VIS1, HC had higher yields of extracted DNA (mean difference
186 of 4.45 ng/ μ L for the measurement with Synergy HTX, 95% CI 1.06–7.84, and mean difference of
187 3.35 ng/ μ L for the measurement with Qubit[®], 95% CI 0.80–5.90; paired t-tests adjusted with FDR).

188 However, while, as expected, the two DNA measurements showed a correlation between each other
189 (Figure S9A: adjusted R^2 of 0.88 and a p -value $< 2.2 \times 10^{-16}$, linear regression model) and the number
190 of cells used for DNA extraction correlated with DNA concentration (Figure S9B: adjusted R^2 of 0.77
191 and a p -value $< 2.2 \times 10^{-16}$, linear regression model), DNA concentration had no effect on mtDNA
192 coverage (Figure S9C–D), with most variability appearing to arise from each sequencing run (Figure
193 S9E–F). Correspondingly, no differences in mtDNA coverage and mappability were found between
194 different subject types (Figure 1B–D and Figure S9E–F).

195 Taking into account all samples analyzed through WGS (Table S7), no contamination was detected
196 and all haplogroups corresponded to European lineages. PwMS had the same haplogroup with two

197 minor exceptions (Triplets #5 and #48) at both visits, albeit without changing their simplified
198 haplogroup (Table S7).

199

200 6.3. Cross-sectional comparison

201 The total number of variants was similar between different subject types, i.e., between HC and
202 PwMS at VIS1 and between VIS1 and VIS2 for PwMS (Figure 2 and Table S7: paired t-tests adjusted
203 with FDR). Variant distribution was also bimodal in all subject types (Figure 2A), likely arising from
204 each sample's haplogroup (Figure 2B–C), since the mean number of variants in HC and PwMS at
205 VIS1 was significantly different in haplogroups with at least three samples (p -value 3.34×10^{-16} ;
206 Kruskal-Wallis test). Haplogroups H and HV had significantly fewer variants (Table S8), which is
207 consistent with the revised Cambridge Reference Sequence (rCRS)'s own H haplogroup [35].
208 Nonetheless, haplogroup distribution was independent from subject type (HC and PwMS at VIS1;
209 Fisher's exact test with Monte Carlo simulations).

210 When comparing HC and PwMS at VIS1, we observed that the total number of variants did not vary
211 according to age (Figure S10A: linear regression model). The difference in the number of mutations
212 between HC and PwMS at VIS1 was also not influenced by sex (Figure S10B–C: two sample t-test
213 [Figure S10B], χ^2 test of independence [Figure S10C], and two-proportions z-test [Figure S10C]).

214 When looking at the differences between PwMS at VIS1 and HC in various mtDNA regions, the
215 highest discordancy in prevalence was in *MT-ND3* for PwMS at VIS1 and in *MT-RNR2* for HC (Figure
216 S11A), while the highest discordant adjusted mutational rate, which is the sum of all VLs in a specific
217 region divided by its region size, was in *MT-TA* for PwMS at VIS1 and in *MT-TT* for HC (Figure S11B).
218 However, there were no significant differences for discordant prevalence (Figure S11A: McNemar's
219 tests adjusted with FDR); nor for other discordant mutational rates (Figure S11B: paired t-tests
220 adjusted with FDR).

221 Regarding macro regions in mtDNA, the most commonly discordant affected region for PwMS at
222 VIS1 was *Other*, which refers to positions in rCRS with an overlap between the two strands or left
223 unannotated, and, for HC, transfer RNA (tRNA) (Figure S11C), while the region with the highest
224 discordant adjusted mutational rate was Complex III for PwMS at VIS1 and *Other* for HC (Figure
225 S11D). Nonetheless, there were no significant differences for discordant prevalence (Figure S11C:

226 McNemar's tests adjusted with FDR); nor for discordant mutational rates (Figure S11D: paired t-
227 tests adjusted with FDR).

228 We further took all variants into account (Table S9), to see if individual variants differed between
229 HC and PwMS at VIS1. However, no significant differences were found (Table S9: McNemar's tests
230 adjusted with FDR). Interestingly, a single PwMS had a pathogenic variant, namely, m.11778G>A in
231 the *MT-ND4* gene (Table S9), which is associated with Leber's hereditary optic neuropathy (LHON)
232 and neuropathy, ataxia, and retinitis pigmentosa (NARP), albeit at low VLs: 5.8% and 7.3% for VIS1
233 and VIS2, respectively; well below the VLs usually required for pathogenesis [36]. The patient in
234 question initially presented with pyramidal and sensory complaints, maintaining the latter
235 throughout their disease course, without any visual changes.

236 Subsequently, we took into account variants predicted *in silico* to be likely deleterious for proteins,
237 defined by a mean value > 0.5 from two independent scores: (I) MutPred [37,38]; and (II) APOGEE
238 [39] (Figure S12 and Figure 3). Nevertheless, the number of deleterious variants (Figure S12A) and
239 the cumulative deleterious burden (Figure 3A), which corresponds to the total sum of a variant's VL
240 multiplied by its deleterious score per sample, did not differ significantly between the different
241 subject types (paired t-tests adjusted with FDR).

242 We observed a similar haplogroup-specific effect for both the number of deleterious mutations and
243 cumulative deleterious burden (Figure S12B–C and Figure 3B–C: p -values 4.61×10^{-13} and 1.38×10^{-15} ,
244 respectively; Kruskal-Wallis tests). Haplogroups J and T had significantly more deleterious
245 variants (Table S10) and cumulative deleterious burden (Table S11).

246 When comparing HC and PwMS at VIS1, the number of deleterious variants did not vary according
247 to age (Figure S13A: Kendall rank correlation test). The difference in the number of deleterious
248 mutations between HC and PwMS at VIS1 was also not influenced by sex (Figure S13B–C: two sample
249 t-test [Figure S13B], χ^2 test of independence [Figure S13C], and two-proportions z-test [Figure
250 S13C]). The same was true for cumulative deleterious burden (linear regression model for age
251 [Figure S13D] and two sample t-test for sex [Figure S13E]).

252 Regarding differences between PwMS at VIS1 and HC in various mtDNA regions, the highest
253 discordancy in prevalence was in *MT-ND5* for PwMS at VIS1 and in *MT-ATP6* for HC (Figure 4A). In
254 parallel, the highest discordant adjusted cumulative deleterious rate, which is the cumulative
255 deleterious rate for a specific region relative to its region size, was in *MT-ND3* for PwMS at VIS1 and

256 in *MT-ATP6* for HC (Figure 4B). Regardless, no significant differences were found for discordant
257 prevalence (Figure 4A: McNemar's tests adjusted with FDR); nor for discordant cumulative
258 deleterious rates (Figure 4B: paired t-tests adjusted with FDR).

259 Regarding macro regions in mtDNA, the most commonly discordant affected region was Complex I
260 for PwMS at VIS1 and Complex V for HC (Figure 4C), while the region with the highest adjusted
261 cumulative deleterious rate was Complex III for PwMS at VIS1 and Complex V for HC (Figure 4D).
262 However, there were no significant differences for discordant prevalence (Figure 4C: McNemar's
263 tests adjusted with FDR); nor for cumulative deleterious rate (Figure 4D: paired t-tests adjusted with
264 FDR).

265 Finally, we looked into tRNA mutations predicted to be pathogenic according to the MitoTIP score
266 [40]: no variants were found (Figure S14A). The cumulative MitoTIP score, which corresponds to the
267 total sum of a variant's VL multiplied by its MitoTIP score per sample, was similar in all subject types
268 (Figure S14B–C: paired t-tests adjusted with FDR).

269 Nonetheless, as observed previously, haplogroup had a significant influence in the cumulative
270 MitoTIP score (Figure S14B–C: p -value 3.59×10^{-13} ; Kruskal-Wallis test), with haplogroups K and U
271 having higher cumulative MitoTIP scores, whereas haplogroups H and HV had lower scores (Table
272 S12). No influence was found regarding age (Figure S14D: linear regression model); or sex (Figure
273 S14E: two sample t-test). The region with the highest discordant adjusted cumulative MitoTIP rate,
274 which is the cumulative MitoTIP rate for a specific region relative to its region size, was *MT-TA* for
275 PwMS at VIS1 and *MT-TT* for HC (Figure S14F). However, no significant differences were found
276 (paired t-tests adjusted with FDR).

277

278 6.4. Longitudinal comparison

279 As mentioned previously, there were no significant differences between PwMS at VIS1 and at VIS2
280 (paired t-tests adjusted with FDR) concerning total number of variants (Figure 2A), number of
281 deleterious variants (Figure S12A), cumulative deleterious burden (Figure 3A), and cumulative
282 MitoTIP score (Figure S14B).

283 The mean proportion of mutations present in a single visit — novel variants — were 4.01% (range:
284 0.00–53.33%) for VIS1 and 3.38% (range: 0.00–37.14%) for VIS2 (Figure 5A), with mean VLs of 8.39%

285 (range: 2.50–100.00%) for VIS1 and 4.66% (range: 2.50–19.60%) for VIS2 (Figure 5B); no significant
286 differences were found between different visits (paired t-tests).

287 Subsequently, we considered the difference in VLs for the previously found variants between the
288 second and the first visits — old variants. The mean VL change was 0.06% in all variants (Figure 5C)
289 and 0.09% per subject (Figure 5D) (range: -10.90–50.30%). Both VL changes were statistically similar
290 to zero (one-sample t-test).

291 When we compared novel and old variants, novel variants had a significantly lower VL than old
292 variants (Figure S15A: adjusted p -value 1.80×10^{-150} ; two-sample t-test adjusted with FDR) and a
293 lower coverage ratio (Figure S15C: adjusted p -value 1.09×10^{-6} ; two-sample t-test adjusted with
294 FDR). There were no significant differences for other quality control variables [29] (Figure S15B and
295 Figure S15D–E; two-sample t-tests adjusted with FDR), nor for protein deleterious score and MitoTIP
296 score (Figure S15F–G; two-sample t-tests adjusted with FDR).

297 Since each PwMS had a very similar mutational pattern between the two visits, we then moved on
298 from an intrapersonal comparison to an interpersonal comparison, with a focus on exploring the
299 origin of these novel variants and the VL change in old variants in the full PwMS cohort. For that
300 purpose, we considered a PwMS as a single data point, where we performed the mean of the results
301 from both sequencing runs.

302 Afterwards, we considered the various possible causes or cofactors behind differences in the
303 proportion of novel variants, VLs of novel variants or VL change in old variants. Haplogroup (Figures
304 S16–18A; Kruskal-Wallis test), age (Figures S16–18B; linear regression model), and sex (Figures S16–
305 18C; two sample t-test) did not influence the aforementioned WGS variables. Interestingly, different
306 regions had a significant effect on the proportion of novel variants, excluding patients without novel
307 variants and regions with mutations from less than three paired samples (Figure S16D: p -value 5.90
308 $\times 10^{-6}$; Kruskal-Wallis test), where *MT-TI* had the highest prevalence and D-loop the lowest (Table
309 S13). This effect was absent for VLs of novel variants or VL change in old variants (Figures S17–18D;
310 Kruskal-Wallis test).

311 Regarding the clinical variables in the cohort, change in MS medication status, i.e., Yes vs. No (Table
312 1 and Table S14), was independent from diagnostic evolution (Figure S19: Fisher's exact test with
313 Monte Carlo simulations).

314 To identify associations of clinical disability with diagnostic evolution, we performed batch Kruskal-
315 Wallis tests with diagnostic evolution as a grouping variable for each available clinical variable
316 (Figure S20 and Figure S21). Two different approaches were tested: (I) the mean of each clinical
317 variable between VIS1 and VIS2 (Figure S20); and (II) the change of each clinical variable from VIS1
318 to VIS2, by subtracting VIS2 and VIS1 (Figure S21). After multiple comparison correction with FDR,
319 only the mean values of the number and volume of T2 hyperintense lesions were associated with
320 diagnostic change (Table S15).

321 Similarly, we performed batch Kruskal-Wallis tests with diagnostic evolution as a grouping variable
322 for each WGS variable explained previously (Figure S22); no significant differences were found
323 (Table S16). Additionally, haplogroup was independent from diagnostic evolution (Figure S23:
324 Fisher's exact test with Monte Carlo simulations). Similarly, as a post hoc analysis, dividing patients
325 according to NEDA-3 status (Table 1 and Figure S24) or cumulative deleterious burden (Figures S25–
326 26) yielded null results.

327

328 7. Discussion

329 The present study investigated whether mitochondrial genotype in CD4⁺ T cells influenced MS
330 disease activity and progression. Accordingly, we performed WGS from CD4⁺ T cells in a matched
331 cohort of PwMS. Overall, however, there were no significant differences regarding number of
332 variants, number of deleterious variants, cumulative protein deleterious burden, or cumulative
333 MitoTIP score between PwMS and HC, nor after a mean of 30.50 months of follow-up between VIS1
334 and VIS2 for PwMS.

335 Importantly, the CIS/RRMS cohort herein described is representative of the overall population of
336 PwMS in Germany, regarding mean age at onset, female predominance, and distribution of the
337 diagnoses, with a vast majority of RRMS [41].

338 According to the flow cytometry analysis performed in a subset of magnetically enriched samples,
339 CD4⁺ T cell enrichment was successful with the MojoSort™ Human CD4 T Cell Isolation Kit, which
340 was expected [42]. The Precision ID mtDNA Whole Genome Panel, in combination with the PCP
341 pipeline [29], proved particularly valuable, as it was able to obtain mtDNA WGS from all samples

342 without signs of contamination, despite a wide range of the number of cells after processing the
343 samples, and, consequently, of DNA yield, which is consistent with previous reports [43].
344 Curiously, amongst the 21 most prevalent mutations in PwMS, five had already been associated with
345 MS, ranging from case reports to large epidemiological studies [16,18,44–46]. Furthermore,
346 remarkably, the high number of deleterious variants in complex I and IV matches the pattern of
347 decreased activity in these complexes in CD4⁺ T cells of PwMS in previous studies [9,47]. Moreover,
348 the higher number of deleterious variants and cumulative deleterious burden from haplogroups J
349 and T is consistent with previous reports of increased MS risk for these haplogroups [16,17].
350 Nevertheless, in our cohort, the mitochondrial genotype did not differ significantly between PwMS
351 and HC, nor between VIS1 and VIS2 within PwMS, which is consistent with previous mtDNA WGS
352 studies in PwMS [19,20].
353 In contrast to the 35% discordance in prevalence for deleterious variants in Complex I registered in
354 the pilot study, the final difference was 18%, due to an increase in prevalence of 8% for HC, while in
355 PwMS it decreased by 9%. Thus, our sample size was incompatible with the previously-set endpoint.
356 A further limitation might have also been the mtDNA WGS of the very heterogenous CD4⁺ T cell
357 compartment, as well as its magnetic enrichment, as opposed to other methods aimed at achieving
358 higher cell purity. Nonetheless, previous studies focused on CD4⁺ T cell OxPhos dysfunction in
359 patients with MS employing magnetic enrichment and fewer subjects than the present cohort were
360 still successful in defining a clear mitochondrial phenotype [9,47].
361 Despite these limitations, this study constitutes a thorough cross-sectional and longitudinal analysis
362 of mtDNA WGS in PwMS, in addition to surveying mitochondrial genotype specifically in CD4⁺ T cells.
363 Moreover, we were able to assess the longitudinal dynamics of mtDNA, which have only very
364 recently started to be unveiled [48,49].
365 Overall, CD4⁺ T cell mitochondrial genotype was not associated with a diagnostic of CIS/RRMS, nor
366 with longitudinal diagnostic evolution. We further postulate that mitochondrial dysfunction in CD4⁺
367 T cells is unlikely to derive from mitochondrial genotype.

368

369 8. References

- 370 1. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. *Nat Rev Immunol*.
371 2015;15:545–58.
- 372 2. Multiple Sclerosis International Federation. Atlas of MS – 3rd Edition. Part 1: Mapping multiple
373 sclerosis around the world. Key epidemiology findings [Internet]. 2020 [cited 2022 Aug 26]. Available
374 from: <https://www.atlasofms.org/>
- 375 3. Gerdes LA, Janoschka C, Eveslage M, Mannig B, Wirth T, Schulte-Mecklenbeck A, et al. Immune
376 signatures of prodromal multiple sclerosis in monozygotic twins. *Proc Natl Acad Sci*.
377 2020;117:21546–56.
- 378 4. Cruciani C, Puthenparampil M, Tomas-Ojer P, Jelcic I, Docampo MJ, Planas R, et al. T-Cell
379 Specificity Influences Disease Heterogeneity in Multiple Sclerosis. *Neurol - Neuroimmunol*
380 *Neuroinflammation*. 2021;8:e1075.
- 381 5. Böttcher C, Fernández-Zapata C, Schlickeiser S, Kunkel D, Schulz AR, Mei HE, et al. Multi-
382 parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass
383 cytometry in patients with early multiple sclerosis. *Sci Rep*. 2019;9:19471.
- 384 6. Bar-Or A, Li R. Cellular immunology of relapsing multiple sclerosis: interactions, checks, and
385 balances. *Lancet Neurol*. Elsevier; 2021;20:470–83.
- 386 7. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al. Mitochondrial DNA
387 deletions and neurodegeneration in multiple sclerosis. *Ann Neurol*. John Wiley & Sons, Ltd;
388 2011;69:481–92.
- 389 8. Witte ME, Nijland PG, Drexhage JAR, Gerritsen W, Geerts D, van het Hof B, et al. Reduced
390 expression of PGC-1 α partly underlies mitochondrial changes and correlates with neuronal loss in
391 multiple sclerosis cortex. *Acta Neuropathol (Berl)*. 2013;125:231–43.
- 392 9. De Riccardis L, Rizzello A, Ferramosca A, Urso E, De Robertis F, Danieli A, et al. Bioenergetics profile
393 of CD4⁺ T cells in relapsing remitting multiple sclerosis subjects. *J Biotechnol*. 2015;202:31–9.

- 394 10. La Rocca C, Carbone F, De Rosa V, Colamatteo A, Galgani M, Perna F, et al. Immunometabolic
395 profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment
396 in glycolysis and mitochondrial respiration. *Metabolism*. 2017;77:39–46.
- 397 11. De Biasi S, Simone AM, Bianchini E, Lo Tartaro D, Pecorini S, Nasi M, et al. Mitochondrial
398 functionality and metabolism in T cells from progressive multiple sclerosis patients. *Eur J Immunol*.
399 2019;49:2204–21.
- 400 12. Zhang D, Jin W, Wu R, Li J, Park S-A, Tu E, et al. High Glucose Intake Exacerbates Autoimmunity
401 through Reactive-Oxygen-Species-Mediated TGF- β Cytokine Activation. *Immunity*. 2019;51:671-
402 681.e5.
- 403 13. Luu M, Pautz S, Kohl V, Singh R, Romero R, Lucas S, et al. The short-chain fatty acid pentanoate
404 suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. *Nat*
405 *Commun*. 2019;10:760.
- 406 14. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. *Nat Rev Genet*.
407 2005;6:389–402.
- 408 15. Weissensteiner H, Pacher D, Kloss-Brandstätter A, Forer L, Specht G, Bandelt H-J, et al.
409 HaploGrep 2: mitochondrial haplogroup classification in the era of high-throughput sequencing.
410 *Nucleic Acids Res*. 2016;44:W58-63.
- 411 16. Yu X, Koczan D, Sulonen A-M, Akkad DA, Kroner A, Comabella M, et al. mtDNA nt13708A Variant
412 Increases the Risk of Multiple Sclerosis. *PLOS ONE*. Public Library of Science; 2008;3:e1530.
- 413 17. Tranah GJ, Santaniello A, Caillier SJ, D’Alfonso S, Martinelli Boneschi F, Hauser SL, et al.
414 Mitochondrial DNA sequence variation in multiple sclerosis. *Neurology*. 2015;85:325–30.
- 415 18. Yonova-Doing E, Calabrese C, Gomez-Duran A, Schon K, Wei W, Karthikeyan S, et al. An atlas of
416 mitochondrial DNA genotype-phenotype associations in the UK Biobank. *Nat Genet*. 2021;53:982–
417 93.

- 418 19. Souren NYP, Gerdes LA, Kümpfel T, Lutsik P, Klopstock T, Hohlfeld R, et al. Mitochondrial DNA
419 Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis. Hum
420 Mutat. 2016;37:765–75.
- 421 20. Pienaar IS, Mohammed R, Courtley R, Gledson MR, Reynolds R, Nicholas R, et al. Investigation
422 of the correlation between mildly deleterious mtDNA Variations and the clinical progression of
423 multiple sclerosis. Mult Scler Relat Disord. 2021;53:103055.
- 424 21. Uittenbogaard M, Brantner CA, Fang Z, Wong L-J, Gropman A, Chiaramello A. The m.11778 A >
425 G variant associated with the coexistence of Leber’s hereditary optic neuropathy and multiple
426 sclerosis-like illness dysregulates the metabolic interplay between mitochondrial oxidative
427 phosphorylation and glycolysis. Mitochondrion. 2019;46:187–94.
- 428 22. Beadnell TC, Fain C, Vivian CJ, King JCG, Hastings R, Markiewicz MA, et al. Mitochondrial genetics
429 cooperate with nuclear genetics to selectively alter immune cell development/trafficking. Biochim
430 Biophys Acta BBA - Mol Basis Dis. 2020;1866:165648.
- 431 23. Walker MA, Lareau CA, Ludwig LS, Karaa A, Sankaran VG, Regev A, et al. Purifying Selection
432 against Pathogenic Mitochondrial DNA in Human T Cells. N Engl J Med. 2020;383:1556–63.
- 433 24. Charite University, Berlin, Germany. Clinically Isolated Syndrome and Newly Diagnosed Multiple
434 Sclerosis: Diagnostic, Prognostic and Therapy - Response Markers - a Prospective Observational
435 Study (Berlin CIS-COHORT) [Internet]. clinicaltrials.gov; 2011 Jun. Report No.: NCT01371071.
436 Available from: <https://clinicaltrials.gov/ct2/show/NCT01371071>
- 437 25. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple
438 sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.
- 439 26. Lin T-Y, Vitkova V, Asseger S, Martorell Serra I, Motamedi S, Chien C, et al. Increased Serum
440 Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for
441 Disease Activity in Early Multiple Sclerosis. Neurol Neuroimmunol Neuroinflammation.
442 2021;8:e1051.

- 443 27. Dupont WD. Power calculations for matched case-control studies. *Biometrics*. 1988;44:1157–
444 68.
- 445 28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles
446 for medical research involving human subjects. *JAMA*. 2013;310:2191–4.
- 447 29. Cortes-Figueiredo F, Carvalho FS, Fonseca AC, Paul F, Ferro JM, Schönherr S, et al. From Forensics
448 to Clinical Research: Expanding the Variant Calling Pipeline for the Precision ID mtDNA Whole
449 Genome Panel. *Int J Mol Sci*. 2021;22:12031.
- 450 30. Weissensteiner H, Forer L, Fuchsberger C, Schöpf B, Kloss-Brandstätter A, Specht G, et al.
451 mtDNA-Server: next-generation sequencing data analysis of human mitochondrial DNA in the cloud.
452 *Nucleic Acids Res*. 2016;44:W64-69.
- 453 31. Weissensteiner H, Forer L, Fendt L, Kheirkhah A, Salas A, Kronenberg F, et al. Contamination
454 detection in sequencing studies using the mitochondrial phylogeny. *Genome Res*. 2021;
- 455 32. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna,
456 Austria: R Foundation for Statistical Computing; 2021 [cited 2022 Feb 2]. Available from:
457 <https://www.R-project.org/>
- 458 33. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
459 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
460 guidelines for reporting observational studies. *Epidemiol Camb Mass*. 2007;18:800–4.
- 461 34. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, et al. STrengthening the
462 REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. *PLoS*
463 *Med*. 2009;6:e22.
- 464 35. Bandelt H-J, Kloss-Brandstätter A, Richards MB, Yao Y-G, Logan I. The case for the continuing use
465 of the revised Cambridge Reference Sequence (rCRS) and the standardization of notation in human
466 mitochondrial DNA studies. *J Hum Genet*. 2014;59:66–77.

- 467 36. Chung C-Y, Valdebenito GE, Chacko AR, Duchon MR. Rewiring cell signalling pathways in
468 pathogenic mtDNA mutations. *Trends Cell Biol.* 2021;S0962892421002075.
- 469 37. Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, et al. Automated inference of molecular
470 mechanisms of disease from amino acid substitutions. *Bioinforma Oxf Engl.* 2009;25:2744–50.
- 471 38. Pereira L, Soares P, Radivojac P, Li B, Samuels DC. Comparing phylogeny and the predicted
472 pathogenicity of protein variations reveals equal purifying selection across the global human mtDNA
473 diversity. *Am J Hum Genet.* 2011;88:433–9.
- 474 39. Castellana S, Fusilli C, Mazzoccoli G, Biagini T, Capocefalo D, Carella M, et al. High-confidence
475 assessment of functional impact of human mitochondrial non-synonymous genome variations by
476 APOGEE. *PLoS Comput Biol.* 2017;13:e1005628.
- 477 40. Sonney S, Leipzig J, Lott MT, Zhang S, Procaccio V, Wallace DC, et al. Predicting the pathogenicity
478 of novel variants in mitochondrial tRNA with MitoTIP. *PLOS Comput Biol. Public Library of Science;*
479 *2017;13:e1005867.*
- 480 41. Ohle L-M, Ellenberger D, Flachenecker P, Friede T, Haas J, Hellwig K, et al. Chances and challenges
481 of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. *Sci*
482 *Rep.* 2021;11:13340.
- 483 42. Godinho-Santos A, Foxall RB, Antão AV, Tavares B, Ferreira T, Serra-Caetano A, et al. Follicular
484 Helper T Cells Are Major Human Immunodeficiency Virus-2 Reservoirs and Support Productive
485 Infection. *J Infect Dis.* 2020;221:122–6.
- 486 43. Faccinnetto C, Sabbatini D, Serventi P, Rigato M, Salvoro C, Casamassima G, et al. Internal
487 validation and improvement of mitochondrial genome sequencing using the Precision ID mtDNA
488 Whole Genome Panel. *Int J Legal Med.* 2021;135:2295–306.
- 489 44. Kalman B, Lublin FD, Alder H. Characterization of the mitochondrial DNA in patients with multiple
490 sclerosis. *J Neurol Sci.* 1996;140:75–84.

491 45. Vyshkina T, Sylvester A, Sadiq S, Bonilla E, Canter JA, Perl A, et al. Association of common
492 mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol
493 Orlando Fla. 2008;129:31–5.

494 46. Andalib S, Emamhadi M, Yousefzadeh-Chabok S, Salari A, Sigaroudi AE, Vafaei MS. MtDNA
495 T4216C variation in multiple sclerosis: a systematic review and meta-analysis. Acta Neurol Belg.
496 2016;116:439–43.

497 47. De Riccardis L, Ferramosca A, Danieli A, Trianni G, Zara V, De Robertis F, et al. Metabolic response
498 to glatiramer acetate therapy in multiple sclerosis patients. BBA Clin. 2016;6:131–7.

499 48. Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, et al. Longitudinal Single-Cell
500 Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia
501 Mirror Disease History. Cancer Discov. 2021;

502 49. Wang Y, Guo X, Ye K, Orth M, Gu Z. Accelerated expansion of pathogenic mitochondrial DNA
503 heteroplasmies in Huntington’s disease. Proc Natl Acad Sci. 2021;118:e2014610118.

504

505 9. Acknowledgements

506 We would like to thank Ana Mafalda Rocha, Bettina Vogelreuter, Bibiane Seeger-Schwinge, Filipa S.
507 Carvalho, Jana Hermann, René Gieß, and Rosalie Schmidt for their support in the conduction of this
508 study. Additionally, we would like to thank Susan Pikol and Cynthia Kraut for their MRI lesion
509 segmentations and collection of MRI data related to this study. We would also like to thank the Flow
510 Cytometry Facility of the Instituto de Medicina Molecular João Lobo Antunes for their technical
511 support, particularly Diana Macedo. Finally, we would like to express our most sincere gratitude to
512 all the subjects who have participated in this research project.

513

514 10. Author contributions

515 F.C.F. was responsible for: Conceptualization of the research study, execution of the experimental
516 tasks, data analysis, and manuscript draft preparation. S.A. was responsible for: Clinical data

517 curation and collection, subject recruitment, critical review of the study's conceptualization, and
518 manuscript revision. C.C. was responsible for: MRI data collection and management, MRI data
519 analysis, and manuscript revision. H.G.Z. was responsible for: OCT data analysis and management,
520 and manuscript revision. K.R. was responsible for: Clinical data collection, subject recruitment, and
521 manuscript revision. T.S.-H. was responsible for: Cohort management, clinical data collection,
522 subject recruitment, project administration, and manuscript revision. J.B.-S. was responsible for:
523 Cohort management, clinical data collection, subject recruitment, project administration, critical
524 review of the study's conceptualization, and manuscript revision. F.P. and V.A.M. were responsible
525 for: Conceptualization of the research study, funding acquisition, provision of resources, supervision
526 of data interpretation, and manuscript revision (co-senior authors). All authors read and approved
527 the final manuscript.

528

529 11. Data availability statement

530 Participant consent did not include sharing of individual study data. Data may be made available for
531 the purpose of replication of results upon reasonable request from the corresponding authors.

532

533 12. Additional information

534 12.1. Funding

535 This research was funded by Merck Germany (restricted research grant), the National Multiple
536 Sclerosis Society (NMSS), NMSS Pilot Research Grant (PP-1712-29466), and Fundação para a Ciência
537 e Tecnologia (FCT) (FCT/PTDC/MED-NEU/7976/2020). F.C.F.'s stipend was supported by FCT
538 (PD/BD/114122/2015) and by Merck Germany (restricted research grant). V.A.M. is an iFCT
539 researcher (IF/01693/2014; IMM/CT/27-2020). The NeuroCure Clinical Research Center (NCRC) is
540 funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under
541 Germany's Excellence Strategy—EXC-2049—390688087 (granted to F.P.).

542 We would also like to acknowledge the Fundos Europeus Estruturais e de Investimento (FEEI) from
543 Programa Operacional Regional de Lisboa 2020 and FCT, grants LISBOA-01-0145-FEDER-016394,

544 LISBOA-01-0145-FEDER-016417, and POCI-01-0145-FEDER-022184, as well as PPBI-POCI-01-0145-
545 FEDER-022122.

546 Funding sources had no influence on the collection, analysis, and interpretation of data, nor in
547 writing the manuscript.

548

549 [12.2. Competing interests](#)

550 F.C.F. reports no disclosures relevant to the manuscript. S.A. received speaker's honoraria from
551 Alexion, Bayer and Roche. C.C. received speaking honoraria from Bayer and research funding from
552 Novartis, unrelated to the current study. H.G.Z. received speaking honoraria from Bayer and
553 Novartis and research funding from Novartis, unrelated to the current study. K.R. received research
554 support from Novartis Pharma, Merck Serono, German Ministry of Education and Research,
555 European Union (821283-2), Stiftung Charité, Guthy Jackson Charitable Foundation and Arthur
556 Arnstein Foundation; received travel grants from Guthy Jackson Charitable Foundation. K.R. is a
557 participant in the BIH Clinical Fellow Program funded by Stiftung Charité. T.S.-H. reports no
558 disclosures relevant to the manuscript. J.B.-S. received speaking honoraria and travel grants from
559 Bayer Healthcare, and sanofi-aventis/Genzyme, in addition received compensation for serving on a
560 scientific advisory board of Roche, unrelated to the presented work. F.P. serves as an Associate
561 Editor for Neurology: Neuroimmunology & Neuroinflammation and PLoS ONE, reports speaker
562 honoraria and/or travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme,
563 Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, and Celgene, research support
564 from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion, Merck Serono, German
565 Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education
566 and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU
567 FP7 Framework Program (combims.eu), Arthur Arnstein Foundation Berlin, Guthy Jackson
568 Charitable Foundation, and National Multiple Sclerosis Society of the USA, consultancies for Sanofi-
569 Aventis / Genzyme, Biogen Idec, MedImmune, Shire, and Alexion, and is a member of the steering
570 committee of the OCTIMS study (Novartis). V.A.M. reports no disclosures relevant to the
571 manuscript.

572

573 12.3. List of abbreviations

574 **bp(s)** — base pair(s)

575 **CI** — confidence interval

576 **CIS** — Clinically Isolated Syndrome

577 **EDSS** — expanded disability status scale

578 **FDR** — false discovery rate

579 **GCIPL** — ganglion cell-inner plexiform layer

580 **gd** — gadolinium

581 **HC** — healthy control(s)

582 **IRB** — institutional review board

583 **les** — lesions

584 **LHON** — Leber's hereditary optic neuropathy

585 **MS** — Multiple Sclerosis

586 **MSFC** — Multiple Sclerosis functional composite

587 **mtDNA** — mitochondrial DNA

588 **N** — number

589 **NARP** — neuropathy, ataxia, and retinitis pigmentosa

590 **NEDA** — no evidence of disease activity

591 **NUMT(s)** — nuclear insertion(s) of mitochondrial DNA

592 **OCT** — optical coherence tomography

593 **OxPhos** — oxidative phosphorylation

594 **PBMC** — peripheral blood mononuclear cell

595 **PCP** — PrecisionCallerPipeline

596 **PwMS** — patient(s) with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis

597 **rCRS** — revised Cambridge Reference Sequence

598 **RRMS** — Relapsing-Remitting Multiple Sclerosis

599 **rRNA** — ribosomal RNA


600 **tRNA** — transfer RNA

601 **TSS** — Ion Torrent Suite™ Software


602 **V** — volume

603 **V1** — patient(s) with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 1,
604 six months after disease onset
605 **V2** — patient(s) with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 2,
606 36 months after disease onset
607 **VIS1** — visit 1
608 **VIS2** — visit 2
609 **VL(s)** — variant level(s)
610 **WGS** — whole genome sequencing
611

612 13. Figures



613
614 **Figure 1 — CD4⁺ T cell enrichment and mitochondrial DNA whole genome sequencing**
615 (A) Percentage of CD4⁺ T cells (CD3⁺ CD4⁺ CD56⁻ CD19⁻) before and after magnetic enrichment, as assessed with flow cytometry —
616 lines connect the same sample; (B) Mean mappability, per subject type and per definition — error bars denote minimum and
617 maximum values; (C) Mean mtDNA coverage, per subject type; (D) Median mtDNA coverage, per subject type. Abbreviations: HC —
618 healthy control; mtDNA — mitochondrial DNA; V1 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple
619 Sclerosis at visit 1; V2 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 2.



620

621

622


623

624

625

Figure 2 — Total number of variants: Cross-sectional comparison (subject types and haplogroups)

(A) Number of variants, per subject type; (B) Number of variants, per subject type and per haplogroup; (C) Expansion of **Figure 2B** for better visualization. Abbreviations: HC — healthy control; V1 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 1; V2 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 2.



626

627

628

629

630

631

632

Figure 3 — Cumulative deleterious burden: Cross-sectional comparison (subject types and haplogroups)

(A) Cumulative deleterious burden, per subject type; (B) Cumulative deleterious burden, per subject type and haplogroup; (C) Expansion of **Figure 3B** for better visualization. Abbreviations: HC — healthy control; V1 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 1; V2 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 2.




Figure 4 — Deleterious variants: Cross-sectional comparison (regions)

(A,C) Discordant prevalence of deleterious variants for each mtDNA coding region/locus and for each macro mtDNA coding region, per subject type, respectively; (B,D) Relative cumulative deleterious burden for each mtDNA coding region/locus and for each macro mtDNA coding region, per subject type, respectively. Abbreviations: bp — base pair; HC — healthy control; V1 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 1.

633


634

635

636

637

638



639

640

641

642

643

644

645

Figure 5 — Longitudinal changes in PwMS: Intrapersonal changes

(A) Proportion of novel variants, per subject and clinical visit; (B) Mean variant level of novel variants, per subject and clinical visit; (C–D) Density plots of variant level change in old variants, for all mutations and per subject, respectively. Abbreviations: PwMS — patients with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis; V1 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 1; V2 — patient with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 2; VL — variant level.

646 14. Tables

647 **Table 1 — Cohort characteristics**

Variables	HC	PwMS		N (existing data at both VIS1 and VIS2)
		V1	V2	
Age at cohort entry (years)	32.78 [19–55]	32.52 [21–56]	-	61
Females		N=40 (66%)		
Date of PBMC collection	2015/06 – 2019/05	2011/05 – 2015/05	2014/01 – 2017/11	61
Diagnostic evolution	-	CIS - CIS, N=14 (23%) CIS - RRMS, N=8 (13%) RRMS - RRMS, N=39 (64%)		61
Immunomodulatory treatment	-	N=16 (26%)	N=29 (48%)	61
EDSS	-	1.50 [0.00–3.50], N=61	1.50 [0.00–4.00], N=60	60
N. relapses	-	0.00 [0.00–1.00], N=61	0.00 [0.00–5.00], N=61	61
Time to last relapse(days)	-	164.85 [29.00– 234.00], N=60	898.10 [10.00– 1187.00], N=61	60
NEDA-3	-	N=9 (15%)		59
MSFC	-	-0.01 [-0.96– 0.76], N=59	0.17 [-1.16–1.01], N=58	57
N. T2 les.	-	6.00 [0.00– 98.00], N=61	8.50 [0.00– 91.00], N=60	60
V. T2 les. (mL)	-	2.04 [0.00– 17.97], N=61	2.52 [0.00– 19.16], N=60	60
N. T1 gd les.	-	0.00 [0.00–3.00], N=49	0.00 [0.00–4.00], N=22	15
V. T1 gd les. (mL)	-	0.01 [0.00–0.28], N=49	0.03 [0.00–0.26], N=22	15
GCIPL (mm ³)	-	1.98 [1.46–2.32], N=51	1.96 [1.44–2.30], N=58	50
RNFL (µm)	-	97.24 [68.00– 126.00], N=54	97.56 [64.50– 132.50], N=58	52

648 Numbers show the mean for each value followed by the minimum and maximum values between brackets, except for EDSS,
649 number of relapses, number of T2 lesions, and number of T1 lesions, where the median value is shown instead of the mean.
650 Abbreviations: EDSS — expanded disability status scale; GCIPL — ganglion cell-inner plexiform layer; gd — gadolinium; HC —
651 healthy controls; les. — lesions; MSFC — Multiple Sclerosis functional composite; N. — number; NEDA — no evidence of disease
652 activity; PBMC — peripheral blood mononuclear cell; PwMS — patients with Clinically Isolated Syndrome/Relapsing-Remitting
653 Multiple Sclerosis; RNFL — retinal nerve fiber layer; V. — volume; V1 — patients with Clinically Isolated Syndrome/Relapsing-
654 Remitting Multiple Sclerosis at visit 1; V2 — patients with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at
655 visit 2; VIS1 — visit 1; VIS2 — visit 2.

656

Table 2 — Magnetic enrichment and DNA extraction: Summary

Subject type	Number of cells after enrichment (millions)	Mortality	DNA (Synergy HTX) (ng/μL)	260/280 ratio	DNA (Qubit®) (ng/μL)
HC	3.03 [0.37–8.92]	15.15% [4.34–70.86%]	20.04 [1.45–65.24]	1.87 [1.19–2.62]	13.78 [1.91–56.00]
V1	2.38 [0.57–6.40]	14.97% [5.57–33.41%]	15.59 [2.93–45.33]	1.89 [1.19–3.37]	10.43 [2.54–37.00]
V2	2.48 [0.10–8.10]	17.73% [7.43–56.25%]	15.94 [3.48–53.46]	1.93 [1.15–5.20]	10.54 [0.70–27.20]
All	2.63 [0.10–8.92]	15.95% [4.34–70.86%]	17.19 [1.45–65.24]	1.90 [1.15–5.20]	11.58 [0.70–56.00]

657

Numbers show the mean for each value followed by the minimum and maximum values between brackets. Abbreviations: HC —

658

healthy controls; V1 — patients with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 1; V2 — patients

659

with Clinically Isolated Syndrome/Relapsing-Remitting Multiple Sclerosis at visit 2.